2024 Prediction from Melynda Barnes, M.D.
Melynda Barnes, M.D. is the Chief Medical Officer at Ro. She believes "more people will gain access to GLP-1 inhibitors" in 2024.
We asked our readers and some members of our editorial advisory board to make predictions for 2024. Here's what Melynda Barnes, M.D., said:
“Telehealth will be better than in-person care for certain chronic conditions. Telehealth offers a scalable solution to one of America’s most plaguing health challenges: obesity.
In 2024, more people will also access care for glucagon-like peptide 1 (GLP-1) inhibitors through direct-to-patient care than in-person providers. We’ll see more people turning to direct-to-patient care as new, more efficacious GLP-1s are introduced.
Employers that offer GLP-1s will poach and retain top talent. Employers that take this risk will reap the benefit of employees incentivized to stay. Survey data even show 44% of people would change jobs to access obesity treatment, and 51% would stay at a job they didn’t like to retain access to obesity treatment.”
Today, the clade 2b outbreak has reached alarming proportions, with over 94,000 confirmed cases reported across 117 countries, including significant numbers in the U.S. and Brazil, and up to 103 deaths. The virus has been found to affect younger men who have sex with men, who are linked to high rates of HIV co-infection.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
